Plexium nabs $102M for protein degradation work weeks after $500M Amgen tie-up

Just weeks after inking a $500 million biobucks pact with Amgen, protein degradation biotech Plexium has secured $102 million in venture capital funds.

The preclinical biotech raised the funds to bankroll work on protein degraders for an immuno-oncology program, a breast cancer asset and a non-small cell lung cancer therapeutic. The San Diego startup has other undisclosed assets in its pipeline, including two from the Amgen tie-up.